

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated April 24, 2026 (the “**Prospectus**”) of Star Sports Medicine Co., Ltd. (北京天星醫療股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong.

Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall, in their sole and absolute discretion, be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — The Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, May 5, 2026).



Starsportned

STAR SPORTS MEDICINE CO., LTD.

北京天星醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

Global Offering

Number of Offer Shares under the : 8,421,850 H Shares
Global Offering
Number of Hong Kong Offer Shares: : 842,200 H Shares
Number of International Offer Shares : 7,579,650 H Shares
Offer Price : HK\$98.50 per H Share, plus brokerage of
1.0%, SFC transaction levy of 0.0027%,
Hong Kong Stock Exchange trading fee of
0.00565% and AFRC transaction levy of
0.00015%
Nominal value : RMB1.00 per H Share
Stock code : 1609

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers*



CITIC SECURITIES



建銀國際
CCB International

*Overall Coordinators, Joint Global Coordinators, Joint Bookrunners
and Joint Lead Managers*



中國銀河國際
CHINA GALAXY INTERNATIONAL



民銀資本
CIBC CAPITAL HOLDINGS LIMITED

Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager



富途證券
FUTU Securities International

Joint Bookrunners and Joint Lead Managers



開盤證券
OPEN SECURITIES



東方證券
— D F Z Q — 國際



浙商國際
ZHEJIANG INTERNATIONAL



Starsportned

STAR SPORTS MEDICINE CO., LTD.

北京天星醫療股份有限公司

ANNOUNCEMENT OF ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated April 24, 2026 (the “**Prospectus**”) of Star Sports Medicine Co., Ltd. (北京天星醫療股份有限公司) (the “**Company**”).*

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company Information	
Stock code	1609
Stock short name	STAR SPORTS MED
Dealings commencement date	May 5, 2026*

* see note at the end of the announcement

Price Information	
Offer Price	HK\$98.50

Offer Shares and Share Capital	
Number of Offer Shares	8,421,850
Number of Offer Shares in Hong Kong Public Offering	842,200
Number of Offer Shares in International Offering	7,579,650
Number of issued Shares upon Listing	54,831,344

Proceeds	
Gross proceeds <i>(Note)</i>	HK\$829.6 million
Less: Estimated listing expenses payable based on Offer Price	HK\$71.2 million
Net proceeds	HK\$758.4 million

Note: Gross proceeds refers to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	300,735
No. of successful applications	16,844
Subscription level	7,823.13 times
Claw-back triggered	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	842,200
No. of Offer Shares reallocated from the International Offering	N/A
Final no. of Offer Shares under the Hong Kong Public Offering	842,200
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	10.00%

Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to the designated results of allocations website at www.eipo.com.hk/eIPOAllotment to perform a search by identification number or the “Allotment Results” page of the White Form eIPO service at www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

No. of places	71
Subscription Level	10.41 times
No. of Offer Shares initially available under the International Offering	7,579,650
No. of Offer Shares reallocated to the Hong Kong Public Offering	N/A
Final no. of Offer Shares under the International Offering	7,579,650
% of Offer Shares under the International Offering to the Global Offering	90.00%

The Directors confirm that, to the best of their knowledge, information and belief, save for a waiver from strict compliance with Rule 10.04 of the Listing Rules, consents under paragraph 1C(2) of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) and Chapter 4.15 of the Guide for New Listing Applicants (“**Listing Guide**”) granted by the Stock Exchange to permit the Company to, among other things, place certain H Shares in the International Offering to existing Shareholders and/or their close associates, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investors

Investor	No. of Offer Shares allocated	% of Offer Shares	% of total issued share capital after the Global Offering	Existing shareholders or their close associates
JSC International Investment Fund SPC (“ JSC International ”) for and on behalf of JSC International Investment Fund SPC-Shanghai SP (“ Shanghai SP ”)	1,968,550	23.37%	3.59%	No
OAP IV (HK) Limited (奧博亞洲四期(香港)有限公司) (“ OAP IV ”) <i>(Note 1)</i>	397,650	4.72%	0.73%	Yes
Greater Bay Area Development Fund Management Limited (大灣區發展基金管理有限公司) (“ GBAD Fund Management ”) for and on behalf of the Managed Account of Mega Prime Development Limited (“ Mega Prime ”)	318,100	3.78%	0.58%	No
GBAD Fund Management for and on behalf of the Managed Account of Poly Platinum Enterprises Limited (“ Poly Platinum ”)	238,600	2.83%	0.44%	No

Note:

- OAP IV is our existing Shareholder. The Company has applied to the Stock Exchange, and the Stock Exchange has granted a waiver under Rule 10.04 of the Listing Rules and a consent under paragraph 1C(2) of the Placing Guidelines in relation to the subscription of the Offer Shares as Cornerstone Investor by OAP IV pursuant to the anti-dilution right. For further details, please refer to the section headed “Waiver from Strict Compliance with the Listing Rules — Waiver under Rule 10.04 and Consent under Paragraph 1C(2) of Appendix F1 to the Listing Rules in Respect of Subscriptions of Offer Shares by Existing Shareholders as Cornerstone Investors” in the Prospectus and the section headed “Allotment Results Details — International Offering — Allottees with waiver/consents obtained” in this announcement.

Allottees with waiver/consents obtained

Investor	No. of Offer Shares allocated	% of Offer Shares	% of total issued share capital after the Global Offering	Relationship
<i>Allottees with consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients^(Note 1)</i>				
China Asset Management (Hong Kong) Limited (“ China AMC ”)	750	0.01%	0.00%	A connected client of CLSA Limited (“ CLSA ”)
China Galaxy International Investment Co., Limited (“ CGII ”)	397,600	4.72%	0.73%	A connected client of China Galaxy International Securities (Hong Kong) Co., Limited (“ CGIS ”)
China Universal Asset Management (Hong Kong) Company Limited (“ China Universal (HK) ”)	500	0.01%	0.00%	A connected client of Orient Securities (Hong Kong) Limited (“ Orient Securities ”)
CITIC Securities International Capital Management Limited (“ CSICM ”)	1,200	0.01%	0.00%	A connected client of CLSA
Orient Asset Management (Hong Kong) Limited (“ Orient AM ”)	4,000	0.05%	0.01%	A connected client of Orient Securities
Hong Kong Haicheng Capital Limited (“ Haicheng Capital ”)	440,300	5.23%	0.80%	A connected client of Orient Securities
<i>Allottees with waiver from strict compliance with Rule 10.04 of the Listing Rules and consent under paragraph 1C(2) of the Placing Guidelines in relation to allocation to existing Shareholders and/or their close associates as Cornerstone Investors or placees^(Note 2)</i>				
CGII	397,600	4.72%	0.73%	A close associate of the Existing Shareholders ^(Note 3)
Haicheng Capital	440,300	5.23%	0.80%	A close associate of the Existing Shareholders
OAP IV ^(Note 4)	397,650	4.72%	0.73%	A cornerstone investor and an existing Shareholder

Notes:

1. For details of the consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients, please refer to the section headed “Additional Information – Placing to connected clients with a prior consent under paragraph 1C(1) of the Placing Guidelines” in this announcement.
2. The Stock Exchange has granted a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a consent under paragraph 1C(2) of the Placing Guidelines to permit Offer Shares to be placed to the above placee who are close associate of certain existing Shareholders. Please refer to the section headed “Additional Information – Placing to close associates of existing Shareholders as placees with a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a prior consent under paragraph 1C(2) of the Placing Guidelines” in this announcement.
3. As defined in Note 6 to the section headed “Additional Information – Placing to close associates of existing Shareholders as placees with a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a prior consent under paragraph 1C(2) of the Placing Guidelines” in this announcement.”
4. As disclosed in the Prospectus, OAP IV, as one of the Pre-IPO Investors, has the right pursuant to the August 2025 Supplemental Agreement to purchase up to the number of ordinary shares of the Company offered in the Global Offering at the Offer Price that enables it to maintain its ownership interest percentage in the Company immediately prior to a qualified IPO (the “**OAP IV Entitled Shares**”) (the “**OAP IV Anti-Dilution Right**”). In the Global Offering, OAP IV will exercise the OAP IV Anti-Dilution Right to subscribe for additional Offer Shares at the Offer Price as a cornerstone investor in the International Offering. Following the exercise of the OAP IV Anti-Dilution Right, OAP IV shall not own more than its percentage shareholding interest in the Company as at immediately before the Global Offering. The Stock Exchange has granted a waiver from strict compliance with Rule 10.04 of the Listing Rules, and a consent under paragraph 1C(2) of the Placing Guidelines, to allow OAP IV to subscribe for Offer Shares in the Global Offering as a cornerstone investor. Such waiver and consent were granted on the basis that, among other things, (a) the allocation to OAP IV is necessary in order to give effect to the OAP IV Anti-Dilution Right under the August 2025 Supplemental Agreement and such allocation will not affect the Company’s ability to satisfy the public float requirement under Rule 8.08 of the Listing Rules; (b) full disclosure of the OAP IV Anti-Dilution Right and the number of shares to be subscribed for by OAP IV will be made in the Prospectus, the allotment results announcement and the placee lists to be submitted to the Stock Exchange; (c) the OAP IV Entitled Shares will be subscribed for by OAP IV at the Offer Price and will not result in the percentage interest held by OAP IV in the Company increasing above the percentage interest held by OAP IV immediately prior to the Global Offering; and (d) the subscription of the OAP IV Entitled Shares by OAP IV will not have any impact on the Shares to be offered to the public investors in Hong Kong under the Hong Kong Public Offering, considering that OAP IV will subscribe for the OAP IV Entitled Shares in the International Offering at the same offer price and under substantially the same terms and conditions as other cornerstone investors in the Global Offering.

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued Shares in the Company upon Listing	Last day subject to the lock-up undertakings <i>(Note 1)</i>
Mr. Dong Wenxing <i>(Note 2)</i>	15,382,400	28.05 %	May 4, 2027
Tianjin Yunkang Technology Center (Limited Partnership) <i>(Note 2)</i>	1,900,000	3.47%	May 4, 2027
Tianjin Puhe Enterprise Management Consulting Partnership (Limited Partnership) <i>(Note 2)</i>	1,094,401	1.99%	May 4, 2027
Tianjin Jikang Enterprise Management Consulting Partnership (Limited Partnership) <i>(Note 2)</i>	871,061	1.59%	May 4, 2027
Subtotal	19,247,862	35.10%	

Notes:

1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Laws. The required lock-up for the Controlling Shareholders ends on May 4, 2026, being 12 months following the Listing Date.
2. The general partner of each of Tianjin Jikang, Tianjin Yunkang and Tianjin Puhe is Tianjin Bokang, which is held as to 99% by Mr. Dong and 1% by Ms. Zhang Di, our Non-Executive Director. Mr. Dong is the sole limited partner of both Tianjin Jikang and Tianjin Puhe. Tianjin Yunkang is an employee shareholding platform with 33 limited partners and Tianjin Bokang as its sole general partner, among which Mr. Dong held 64.77% partnership interest, our executive Director Mr. He Lu, our Supervisors Mr. Xu Jingtao, Mr. Yang Tengfei and Ms. Wang Yali, and our chief operating officer and deputy general manager Mr. Liu Shaobin, held 5.67%, 1.13%, 1.13%, 0.57% and 2.27% partnership interest, respectively, with the remaining partnership interest held by our employees or former employees. None of the other limited partners hold 5% or more in Tianjin Yunkang or served as a Director, Supervisor or senior management of the Company. For further details, see “History, Development and Corporate Structure — OUR EMPLOYEE SHAREHOLDING PLATFORM.”

Pre-IPO Investors (as defined in the Prospectus)

Name	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued Shares in the Company upon Listing	Last day subject to the lock-up undertakings (Note 1)
Xiamen Defu Yuean Investment Partnership Enterprise (Limited Partnership)/廈門德福悅安投資合夥企業(有限合夥)	4,938,004	9.01%	May 4, 2027
Suzhou Junlian Xinkang Venture Investment (Limited Partnership)/蘇州君聯欣康創業投資合夥企業(有限合夥)	4,504,897	8.22%	May 4, 2027
BEST ALIVE LIMITED/沛昕有限公司	2,503,228	4.57%	May 4, 2027
OAP IV (HK) Limited/奧博亞洲四期(香港)有限公司	4,306,666	7.85%	May 4, 2027
Anji Jintian Dinghao Enterprise Management Consulting Partnership (Limited Partnership)/安吉錦天鼎昊管理諮詢合夥企業(有限合夥)	2,276,333	4.15%	May 4, 2027
Ningbo Meishan Bonded Port Qianyi Equity Investment Partnership Enterprise (Limited Partnership)/寧波梅山保稅港區乾怡股權投資合夥企業(有限合夥)	2,057,501	3.75%	May 4, 2027
Beijing Yahui Jinlin Venture Capital Partnership (Limited Partnership)/北京雅惠錦霖創業投資合夥企業(有限合夥)	1,873,568	3.42%	May 4, 2027
Beijing Jianxing Healthcare Industry Equity Investment Partnership (Limited Partnership)/北京建興醫療健康產業股權投資合夥企業(有限合夥)	1,405,177	2.56%	May 4, 2027
Galaxy Yuanhui Investment Co., Ltd/銀河源匯投資有限公司	1,170,980	2.14%	May 4, 2027

Name	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued Shares in the Company upon Listing	Last day subject to the lock-up undertakings (Note 1)
Ningbo Xianda Venture Investment Partnership Enterprise (Limited Partnership)/寧波先達創業投資合夥企業(有限合夥)	702,588	1.28%	May 4, 2027
Taizhou Sida Venture Capital Partnership (Limited Partnership)/台州思達創業投資合夥企業(有限合夥)	224,828	0.41%	May 4, 2027
Khorgos Dadao Venture Capital Co., Ltd./霍爾果斯達創創業投資有限公司	9,368	0.02%	May 4, 2027
Langma No. 61 (Shenzhen) Entrepreneurship Investment Center (Limited Partnership)/朗瑪六十一號(深圳)創業投資中心(有限合夥)	351,294	0.64%	May 4, 2027
Langma No. 62 (Shenzhen) Entrepreneurship Investment Center (Limited Partnership)/朗瑪六十二號(深圳)創業投資中心(有限合夥)	351,294	0.64%	May 4, 2027
3W Rivus Fund	485,906	0.89%	May 4, 2027
Subtotal	27,161,632	49.54%	

Notes:

1. Please see “History, Development and Corporate Structure — Information about our Pre-IPO Investors” in the Prospectus for the identities of the Pre-IPO Investors.
2. Pursuant to the applicable PRC law, within the 12 months following the Listing Date, all existing Shareholders (including the Pre-IPO Investors) are prohibited from disposing of any of the Shares held by them.

Cornerstone Investors

Name	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued Shares in the Company upon Listing	Last day subject to the lock-up undertakings (Note 1)
JSC International for and on behalf of Shenghai SP	1,968,550	3.59%	November 4, 2026
OAP IV	397,650	0.73%	November 4, 2026
GBAD Fund Management for and on behalf of the Managed Account of Mega Prime	318,100	0.58%	November 4, 2026
GBAD Fund Management for and on behalf of the Managed Account of Poly Platinum	238,600	0.44%	November 4, 2026

Note:

- Each of the Cornerstone Investors has agreed that it will not, whether directly or indirectly, at any time during the period of six months from and inclusive of the Listing Date (the “**Lock-up Period**”), dispose of any of the Offer Shares they have purchased pursuant to the relevant Cornerstone Investment Agreements, save for certain limited circumstances, such as transfers to any of its wholly-owned subsidiaries who will be bound by the same obligations of such Cornerstone Investor, including the Lock-up Period restriction.

PLACEE CONCENTRATION ANALYSIS

Placees	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	1,968,550	25.97%	23.37%	1,968,550	3.59%
Top 5	4,408,650	58.16%	52.35%	5,345,434	9.75%
Top 10	6,021,800	79.45%	71.50%	11,265,250	20.55%
Top 25	7,550,850	99.62%	89.66%	12,794,300	23.33%

Note:

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHARE SHAREHOLDER CONCENTRATION ANALYSIS

H Shareholders	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Share capital upon Listing
Top 1	–	0.00%	0.00%	19,247,862	35.10%
Top 5	397,650	5.25%	4.72%	38,174,640	69.62%
Top 10	3,204,100	42.27%	38.05%	47,254,120	86.18%
Top 25	7,033,800	92.80%	83.52%	53,443,294	97.47%

Note:

* Ranking of H Shareholders is based on the number of H Shares held by H Shareholders upon Listing.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	–	0.00%	0.00%	19,247,862	19,247,862	35.10%
Top 5	397,650	5.25%	4.72%	38,174,640	38,174,640	69.62%
Top 10	3,204,100	42.27%	38.05%	47,254,120	47,254,120	86.18%
Top 25	7,033,800	92.80%	83.52%	53,443,294	53,443,294	97.47%

Note:

* Ranking of Shareholders is based on the number of Shares (of all classes) held by Shareholders upon Listing.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

Pool A			
Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of H Shares applied for
50	69,002	1,034 out of 69,002 to receive 50 Shares	1.50%
100	33,023	499 out of 33,023 to receive 50 Shares	0.76%
150	7,906	121 out of 7,906 to receive 50 Shares	0.51%
200	8,839	137 out of 8,839 to receive 50 Shares	0.39%
250	6,365	99 out of 6,365 to receive 50 Shares	0.31%
300	4,315	69 out of 4,315 to receive 50 Shares	0.27%
350	2,525	41 out of 2,525 to receive 50 Shares	0.23%
400	3,268	54 out of 3,268 to receive 50 Shares	0.21%
450	2,640	44 out of 2,640 to receive 50 Shares	0.19%
500	14,849	248 out of 14,849 to receive 50 Shares	0.17%
600	3,021	52 out of 3,021 to receive 50 Shares	0.14%
700	2,213	39 out of 2,213 to receive 50 Shares	0.13%
800	2,195	39 out of 2,195 to receive 50 Shares	0.11%
900	3,215	59 out of 3,215 to receive 50 Shares	0.10%
1,000	11,642	218 out of 11,642 to receive 50 Shares	0.09%
1,500	5,867	119 out of 5,867 to receive 50 Shares	0.07%
2,000	5,426	118 out of 5,426 to receive 50 Shares	0.05%
2,500	4,462	104 out of 4,462 to receive 50 Shares	0.05%
3,000	3,995	99 out of 3,995 to receive 50 Shares	0.04%
3,500	2,804	74 out of 2,804 to receive 50 Shares	0.04%
4,000	2,715	76 out of 2,715 to receive 50 Shares	0.03%
4,500	2,348	69 out of 2,348 to receive 50 Shares	0.03%
5,000	15,606	483 out of 15,606 to receive 50 Shares	0.03%
10,000	10,525	481 out of 10,525 to receive 50 Shares	0.02%
15,000	6,565	397 out of 6,565 to receive 50 Shares	0.02%
20,000	5,554	417 out of 5,554 to receive 50 Shares	0.02%
25,000	4,436	399 out of 4,436 to receive 50 Shares	0.02%
30,000	3,881	406 out of 3,881 to receive 50 Shares	0.02%
35,000	2,806	338 out of 2,806 to receive 50 Shares	0.02%
40,000	2,677	369 out of 2,677 to receive 50 Shares	0.02%
45,000	2,145	332 out of 2,145 to receive 50 Shares	0.02%
50,000	8,074	1,388 out of 8,074 to receive 50 Shares	0.02%
	264,904	Total number of Pool A successful applicants: 8,422	

Pool B

Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of H Shares applied for
60,000	8,471	1,291 out of 8,471 to receive 50 Shares	0.01%
70,000	3,525	567 out of 3,525 to receive 50 Shares	0.01%
80,000	2,918	493 out of 2,918 to receive 50 Shares	0.01%
90,000	2,074	368 out of 2,074 to receive 50 Shares	0.01%
100,000	6,323	1,174 out of 6,323 to receive 50 Shares	0.01%
150,000	3,699	839 out of 3,699 to receive 50 Shares	0.01%
200,000	2,196	589 out of 2,196 to receive 50 Shares	0.01%
250,000	1,528	505 out of 1,528 to receive 50 Shares	0.01%
300,000	1,045	415 out of 1,045 to receive 50 Shares	0.01%
350,000	807	375 out of 807 to receive 50 Shares	0.01%
421,100	<u>3,245</u>	1,806 out of 3,245 to receive 50 Shares	0.01%
	<u>35,831</u>	Total number of Pool B successful applicants: 8,422	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

ADDITIONAL INFORMATION

Placing to connected clients with a prior consent under paragraph 1C(1) of the Placing Guidelines

Under the International Offering, certain Offer Shares were placed to connected clients of certain distributors pursuant to the Placing Guidelines. Details of the placement to connected clients are set out below.

Connected client	Connected distributor	Relationship	Whether the connected client will hold beneficial interests of Offer Shares on a non-discretionary or discretionary basis for independent third parties	No. of Offer Shares allocated to the connected client	% of Offer Shares	% of total issued share capital after the Global Offering
China AMC	CLSA Limited (“CLSA”), Futu Securities International (Hong Kong) Limited (“Futu Securities”)	See Note 1	Discretionary basis	750	0.01%	0.00%
CGII	China Galaxy International Securities (Hong Kong) Co., Limited (“CGIS”)	See Note 2	Non-discretionary basis	397,600	4.72%	0.73%

Connected client	Connected distributor	Relationship	Whether the connected client will hold beneficial interests of Offer Shares on a non-discretionary or discretionary basis for independent third parties	No. of Offer Shares allocated to the connected client	% of Offer Shares	% of total issued share capital after the Global Offering
China Universal (HK)	Orient Securities (Hong Kong) Limited (“Orient Securities”)	See Note 3	Discretionary basis	500	0.01%	0.00%
CSICM	CLSA	See Note 4	Non-discretionary basis	1,200	0.01%	0.00%
Orient AM	Orient Securities	See Note 5	Discretionary basis	4,000	0.05%	0.01%
Haicheng Capital	Orient Securities	See Note 6	Discretionary basis	440,300	5.23%	0.80%

Notes:

1. China AMC is a member of the same group of companies as CLSA, China AMC will hold the Offer Shares in its capacity as discretionary fund manager managing assets on behalf of its underlying clients. To the best of China AMC’s knowledge after due enquiry, each underlying client of China AMC is an independent third party of China AMC, CLSA and the companies which are members of the same group of CLSA; Futu Securities is an ultimate beneficial owner of a fund managed by China AMC.
2. CGII and China Galaxy Securities (“CGS”) will enter into a series of cross border total return swap (TRS) transactions (collectively, the “CGII TRS”) with each other and the ultimate client (“CGII Ultimate Client”), pursuant to which CGII will hold the Offer Shares on a non-discretionary basis to hedge the CGII TRS while the economic risks and returns of the underlying Offer Shares are ultimately borne by the CGII Ultimate Client, subject to customary fees and commissions. The CGII TRS will be fully funded by the CGII Ultimate Client. During the terms of the CGII TRS, all economic returns of the Offer Shares subscribed by CGII will be passed to CGII Ultimate Client and all economic loss shall be borne by CGII Ultimate Client through the CGII TRS, and CGII will not take part in any economic return or bear any economic loss in relation to the Offer Shares.

The CGII Ultimate Client may exercise an early termination right to terminate the CGII TRS at any time from the issue date of the CGII TRS which should be on or after the date on which the Offer Shares are listed on the Stock Exchange. Upon the termination upon maturity or early termination of the CGII TRS by the CGII Ultimate Client, CGII will dispose of the Offer Shares on the secondary market and the CGII Ultimate Client will receive final settlement amount of the back-to-back TRS which should have taken into account all the economic returns or economic loss in relation to the Offer Shares. If upon the maturity of the CGII TRS, the CGII Ultimate Client intends to extend the investment period, subject to further agreement between CGII and the CGII Ultimate Client, the term of the CGII TRS could be extended by way of a new issuance or a tenor extension. Accordingly, CGII will extend the term of the back-to-back TRS by way of a new issuance or a tenor extension.

It is proposed that CGII will hold the legal title and the voting right of the Offer Shares by itself, and pass through the economic exposure to the CGII Ultimate Client, which place CGII TRS orders through their asset manager with CGII in connection with the IPO of the Company. Due to its internal policy, CGII will not exercise the voting right of the Offer Shares during the tenor of the back-to-back TRS.

During the life of the CGII TRS and back-to-back TRS, CGII may continue to hold the Offer Shares in its custodian account, or to hold some or all of the Offer Shares in a prime brokerage account for stock borrowing purposes.

As permitted under the contractual arrangement with the CGII Ultimate Client, CGII will lend out its holding of underlying Offer Shares in the form of stock borrowing loans consistent with market practice to lower its finance costs, provided that CGII has the ability to call back the Offer Shares on loan at any time in order to satisfy its obligations under the back-to-back TRS to ensure the economic interests to be passed to the CGII Ultimate Client under the CGII TRS will remain unchanged.

To the best of CGII's knowledge after having made all reasonable inquiries, the CGII Ultimate Client is an independent third party of CGII, and the companies which are members of the same group of CGIS.

Both CGII and CGIS are indirect wholly-owned subsidiaries of CGS, the A shares of which are listed on the Shanghai Stock Exchange (stock code: 601881), the H shares of which are listed on the Stock Exchange (stock code: 6881). CGII is a connected client (as defined under Appendix F1 to the Listing Rules) of CGIS, holding securities on a non-discretionary basis on behalf of independent third parties.

The CGII Ultimate Client is Hangzhou Haida Bicheng Venture Capital Management Partnership(L.P.) (杭州海達必成創業投資管理合夥企業(有限合夥)) ("**Haida Bicheng**"), a limited partnership established in the PRC, whose general partner is Wang Wengang (王文剛) ("**Mr. Wang**"), who owns 41% of the interest of Haida Bicheng.

3. China Universal (HK) is a member of the same group of companies as Orient Securities. China Universal (HK) will hold the Offer Shares in its capacity as discretionary fund manager managing assets on behalf of its underlying clients. To the best of China Universal (HK)'s knowledge after due enquiry, certain underlying clients of China Universal (HK) have ultimate beneficial owners holding 30% or more interest of the respective discretionary fund, however each underlying client of China Universal (HK) is an independent third party of China Universal (HK), Orient Securities and the companies which are members of the same group of Orient Securities.
4. CITIC Securities Company Limited ("**CITIC Securities**"), the shares of which are listed on both the Shanghai Stock Exchange (stock code: 600030) and the Stock Exchange (stock code: 6030), is one of the domestic securities firms licensed to undertake cross-border derivatives trading activities. CITIC Securities entered into an International Swaps and Derivatives Association agreement (the "**ISDA Agreement**") with its indirectly wholly-owned subsidiary, CSICM to set out the principal terms of any future total return swap between CITIC Securities and CSICM.

CLSA is a sponsor-overall coordinator of the Global Offering. Pursuant to the ISDA Agreement, CSICM, which intends to participate in the Global Offering as a placee, will hold the Offer Shares on a non-discretionary basis as the single underlying holder under a back-to-back total return swap (the "**Back-to-back TRS**") to be entered by CSICM with CITIC Securities in connection with Client TRS (as defined below) placed by and fully funded (i.e. with no financing provided by CSICM) by the CSICM Ultimate Clients (as defined below), pursuant to which CSICM will pass the full economic exposure of the Offer Shares to the CSICM Ultimate Clients, which in effect, CSICM will hold the beneficial interest of the Offer Shares on behalf of the CSICM Ultimate Clients.

Pursuant to the Cross-border Derivatives Trading Regime, the onshore investors (the "**CSICM Ultimate Clients**") cannot directly subscribe for the Offer Shares but may invest in derivative products issued by domestic securities firms licenced to undertake cross-border derivatives trading activities, such as CITIC Securities, with the Offer Shares as the underlying assets. Instead of directly subscribing for the Offer Shares, the CSICM Ultimate Clients will place a total return swap order (the "**Client TRS**") with CITIC Securities in connection with the Company's IPO and CITIC Securities will place Back-to-back TRS orders to CSICM on the terms of the ISDA Agreement. In order to hedge its exposure under the Back-to-back TRS, CSICM participates in the Company's IPO and subscribes the Offer Shares through placing order with CLSA during the International Offering.

The following table sets forth the ultimate beneficial owners of CSICM:

Name (CSICM Ultimate Client)	Asset Manager	UBO of Asset Manager	UBO of CSICM Ultimate Client
Yucheng Xiangjiang Qiming Private Securities Investment Fund* (宇誠香江啟明私募證券投資基金)	Yucheng Private Fund Management (Hainan) Partnership (Limited Partnership)* (宇誠私募基金管理(海南)合夥企業(有限合夥)) (“Yucheng”)	Ma Shuying (馬曙瑩)	Li Jianxue (李建學)
Liangpai Exclusive Fund No. 43 Private Securities Investment Fund* (量派專享四十三號私募證券投資基金)	Shanghai QuantPi Investment Limited (上海量派投資管理有限公司) (“Shanghai Liangpai”)	Sun Lin (孫林), Yu Hang (餘航)	Sun Lin (孫林)
Evolution Darwin Zenshan No. 3 Private Securities Investment Fund* (進化論達爾文上善三號私募證券投資基金)	Evolution Asset Management co., Ltd. (海南進化論私募基金管理有限公司) (“Hainan Evolution”)	Wang Yiping (王一平)	N/A ¹
Tongyi Taoli No. 1 Private Securities Investment Fund* (通怡桃李 1 號私募證券投資基金)	Shanghai Tongyi Investment Management Co., Ltd. (上海通怡投資管理有限公司) (“Shanghai Tongyi”)	Chu Yibo (儲貽波)	Wang Jing (王靜)
Tongyi Taoli No. 10 Private Securities Investment Fund* (通怡桃李 10 號私募證券投資基金)	Shanghai Tongyi Investment Management Co., Ltd. (上海通怡投資管理有限公司)	Chu Yibo (儲貽波)	N/A ²

To the best knowledge of CSICM after making all reasonable enquiries, the CSICM Ultimate Clients are independent third parties of CSICM and CLSA, the companies which are members of the same group of companies as CLSA and the Company.

Pursuant to the terms of the contracts of the Back-to-back TRS and the Client TRS, during the tenor of the Back-to-back TRS and the Client TRS, all economic returns of the Offer Shares will be passed to the CSICM Ultimate Clients through the Back-to-back TRS and the Client TRS and all economic loss shall be borne by the CSICM Ultimate Clients. CSICM and CITIC Securities will not take any economic return or bear any economic loss in relation to the Offer Shares.

The CSICM Ultimate Clients may exercise an early termination right to terminate the Client TRS at any time from the issue date of the Client TRS which should be on or after the date on which the Offer Shares are listed on the Stock Exchange. Upon the termination upon maturity or early termination of the Client TRS by the CSICM Ultimate Clients, CSICM will dispose of the Offer Shares on the secondary market and the CSICM Ultimate Clients will receive final settlement amount of the Back-to-back TRS which should have taken into account all the economic returns or economic loss in relation to the Offer Shares. If upon the maturity of the Client TRS, the CSICM Ultimate Clients intend to extend the investment period, subject to further agreement between CSICM and the CSICM Ultimate Clients, the term of the Client TRS could be extended by way of a new issuance or a tenor extension. Accordingly, CSICM will extend the term of the Back-to-back TRS by way of a new issuance or a tenor extension.

It is proposed that CSICM will hold the legal title and the voting right of the Offer Shares by itself, and pass through the economic exposure to the CSICM Ultimate Clients, which place Client TRS orders through their asset manager with CITIC Securities in connection with the IPO of the Company. Due to its internal policy, CSICM will not exercise the voting right of the Offer Shares during the tenor of the Back-to-back TRS.

During the life of the Client TRS and Back-to-back TRS, CSICM may continue to hold the Offer Shares in its custodian account, or to hold some or all of the Offer Shares in a prime brokerage account for stock borrowing purposes.

As permitted under the contractual arrangement with the CSICM Ultimate Clients, CSICM will lend out its holding of underlying Offer Shares in the form of stock borrowing loans consistent with market practice to lower its finance costs, provided that CSICM has the ability to call back the Offer Shares on loan at any time in order to satisfy its obligations under the Back-to-back TRS to ensure the economic interests to be passed to the CSICM Ultimate Clients under the Client TRS will remain unchanged.

¹ No ultimate beneficial owners holding 30% or more interest

² No ultimate beneficial owners holding 30% or more interest

5. Orient AM will hold the Offer Shares in its capacity as discretionary fund manager managing assets on behalf of its underlying clients under the sub-funds, namely OSR Selective No.4 and OSR Voyage No.16. Orient AM is a member of the same group of companies as Orient Securities. To the best of Orient AM's knowledge after due enquiry, each underlying client of Orient AM is an independent third party of Orient AM, Orient Securities and the companies which are members of the same group of Orient Securities.
6. Haicheng Capital's securities account has been fully entrusted to Orient AM for management, and Orient AM has been granted all investment and trading authority over Haicheng Capital's account. Orient AM is a member of the same group of companies as Orient Securities. Haicheng Capital's ultimate beneficiary owners are Chen Qiao (陳巧) and Wang Wengang (王文剛) ("**Mr. Wang**"), who owns 41% and 40% of the issued capital of Haicheng Capital as of the date of this application.

Ningbo Xianda Venture Investment Partnership Enterprise (Limited Partnership) (寧波先達創業投資合夥企業(有限合夥)) ("**Ningbo Xianda**") is a limited partnership incorporated in the PRC on June 29, 2021. Taizhou Sida Venture Capital Partnership (Limited Partnership) (台州思達創業投資合夥企業(有限合夥)) ("**Taizhou Sida**") is a limited partnership incorporated in the PRC on March 2, 2022. Khorgos Dadao Venture Capital Co., Ltd. (霍爾果斯達創創業投資有限公司) ("**Khorgos Dadao**") is a limited liability company established in the PRC on February 28, 2017. The general partner of Ningbo Xianda and the sole shareholder of Khorgos Dadao is Tianjin Haida Venture Capital Management Co., Ltd. (天津海達創業投資管理有限公司) ("**Tianjin Haida**"), which is ultimately controlled by Mr. Wang, an Independent Third Party of the Company. The general partner of Taizhou Sida is Hangzhou Haida Bicheng Venture Capital Management Partnership(L.P.) (杭州海達必成創業投資管理合夥企業(有限合夥)) ("**Haida Bicheng**"), a limited partnership established in the PRC, whose general partner is Mr. Wang, who owns 41% of the interest of Haida Bicheng. Accordingly, each of Ningbo Xianda, Taizhou Sida and Khorgos Dadao is under the common control of Mr. Wang (together as the "**Existing Shareholders**"). Haida Bicheng, being a company of which Mr. Wang is an ultimate beneficiary owner holding 40% of its issued capital, and Mr. Wang controlling each of the Existing Shareholders, is a close associate of the Existing Shareholders. None of the limited partners holds 30% or more of limited partnership interests in either of Ningbo Xianda, Taizhou Sida and Haida Bicheng.

As of the Latest Practicable Date (as defined in the Prospectus), Ningbo Xianda, Taizhou Sida and Khorgos Dadao held 1.51%, 0.48% and 0.02% of the total issued shares capital of the Company.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraphs 1C(1) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to the connected clients listed above. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consent granted by the Stock Exchange.

Placing to close associates of existing Shareholders as placees with a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a prior consent under paragraph 1C(2) of the Placing Guidelines

The Company has applied to the Stock Exchange, and the Stock Exchange has granted, the waivers from the strict compliance with Rule 10.04 of the Listing Rules and consents under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to close associates (the "**Placees**") of Existing Shareholders (as defined below) on the following grounds which are consistent with the conditions as set out in the Chapter 4.15 of the Guide for New Listing Applicant:

- (a) the Joint Sponsors confirm that:
 - (i) each of the Existing Shareholders is interested in less than 5% of the Company's voting rights before the Listing;
 - (ii) none of the Existing Shareholders or their close associates is a core connected person of the Company or its close associate;

- (iii) none of the Existing Shareholders or their close associates has the power to appoint any Directors to the Board or any other special rights upon the Listing;
 - (iv) as none of the Existing Shareholders or their close associates is a core connected person of the Company or its close associate, allocation to the Placees will not affect the Company's ability to satisfy the public float requirement under Rule 8.08(1) (as amended and replaced by 19A.13A(1) for PRC issuers with no other listed shares) of the Listing Rules; and
 - (v) to the best of their knowledge and belief, no preferential treatment has been, nor will be, given to the Existing Shareholders or their close associates by virtue of their relationship with the Company in any allocation in the placing tranche;
- (b) the Company confirms that no preferential treatment has been, nor will be, given to the Existing Shareholders or their close associates by virtue of their relationship with the Company in any allocation of the placing tranche;
 - (c) the Overall Coordinators confirm that, to the best of their knowledge and belief, no preferential treatment has been, nor will be, given to the Existing Shareholders or their close associates by virtue of their relationship with the Company in any allocation in the placing tranche; and
 - (d) details of the allocation of H Shares to the Existing Shareholders and their close associates will be disclosed in this allotment results announcement.

The allocation of Offer Shares to such Existing Shareholders and/or close associates of the Existing Shareholders is in compliance with all the conditions under the waivers/consents granted by the Stock Exchange.

For details of the allocation of Offer Shares to a close associate of the Existing Shareholders, please refer to the section headed "Allotment Results Details — International Offering — Allottees with waiver/consents obtained" in this announcement.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated April 24, 2026 issued by Star Sports Medicine Co., Ltd. (北京天星醫療股份有限公司) for detailed information about the Global Offering described herein before deciding whether or not to invest in the Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall, in their sole and absolute discretion, be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — The Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, May 5, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Immediately following the completion of the Global Offering, (i) approximately 52.12% of the total number of issued Shares will be regarded as public float and the Company will satisfy the minimum percentage as prescribed under Rule 19A.13A(1) of the Listing Rules; (ii) the three largest public Shareholders do not hold more than 50% of the H Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; (iii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company immediately after the Global Offering; (iv) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; and (v) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

In consideration that the total number of H Shares in issue upon Listing that are held by the public and not subject to any disposal restrictions is expected to be at least 10% of the total issued share capital of the Company, the Company is expected to satisfy the free float requirement under Rule 19A.13C of the Listing Rules at the time of Listing.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. (Hong Kong time) on Tuesday, May 5, 2026, provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting — Underwriting Arrangements and Expenses — The Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised. Investors who trade H Shares prior to the receipt of H Share certificates or the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. (Hong Kong time) on Tuesday, May 5, 2026, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, May 5, 2026. The H Shares will be traded in board lots of 50 H Shares each. The stock code of the Shares is 1609.

By order of the Board
Star Sports Medicine Co., Ltd.
Mr. Dong Wenxing
Chairman of the Board and Executive Director

Hong Kong, May 4, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Dong Wenxing and Mr. He Lu as executive directors; (ii) Ms. Zhang Di, Mr. Chang Xi, Mr. David Guowei Wang, Ms. Yi Lin and Mr. Zhou Quan as non-executive directors and (iii) Mr. Lyu Zhenlin, Mr. Deng Yu, Mr. Liu Baojie and Mr. Wang Chunfei as independent non-executive directors.